Default company panoramic image


CureWize translates biomedical research into clinical practice for improving the treatment of young cancer patients.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location St Albans, GB-ENG, United Kingdom
  • Currency USD
  • Founded January 2013
  • Employees 5
  • Website

Company Summary

Curewize Ltd. is an expert in developing and commercializing biomarker assays. Our lead product, is ProALL, a prognostic test developed at Schneider Children’s’ Medical Center for tailoring and monitoring leukemia patients' treatment. ProALL is markedly better, faster and less costly than the current routinely used tests. The FDA acknowledged the need for improved prognostic assays such as ProALL. ProALL’s natural home market is global.


  • Default avatar
    Dr. Jennifer Sue Yarden

    Former Director of Clinical Development at Glycominds Ltd. Expert in the clinical development and commercialization of in vitro diagnostic and prognostic biomarker kits. Over 15 years’ experience in the scientific, medical and in vitro diagnostic sectors. Jennifer holds a PhD in Medical Science, thesis subject was disease biomarkers for respiratory diseases.

  • Default avatar
    Ossie Weitzman

    Ossie is a UK qualified Chartered Accountant with over 30 years financial management and business development experience. He has worked with a large number of technology companies in the life science and other fields, both in Israel and the UK, assisting them in defining and executing business strategies.

  • Default avatar
    Dr. Smadar Avigad

    Smadar is the co-inventor of the technology. Smadar established and Heads the Molecular Oncology Lab for the Pediatric Hematology Oncology The Department at the Schneider, which serves all of Israel. Smadar's main focus is translational medicine, with an aim of integrating the data obtained in the lab back to the clinic. Smadar has received her PhD from the Tel Aviv University, Department of Human Genetics.

  • Default avatar
    Prof. Isaac Yaniv

    Prof. Yaniv is the Director of the Division of Pediatric Hematology Oncology at Schneider’s Children’s Medical Center of Israel. Board certified in Pediatrics, Hematology and Pediatric Hematology Oncology. He is currently the chairman of the Israeli Society of Pediatric Hematology Oncology and councilor to the Israeli Ministry of Health. Isaac established the first pediatric stem cell transplantation unit in Israel.

  • Default avatar
    Rita Gabay

    Rita is the owner and Manager at QA INSIGHT Ltd. and holds an M.Sc. in Quality Assurance and Reliability from the Technion and an internationally recognized certificate as a Quality Systems auditor. Rita has over 20 years of experience in the pharmaceutical, medical devices and in-vitro diagnostic industry market, Clinical Quality Assurance, and management of Quality Systems compliant with ISO 9001:2008 and 13485:2003 and Regulatory Affairs.